Cap drug prices for Medicare drugs

Summary#

SF-5302 would add a new section to Minnesota Statutes, chapter 62Q; it does not amend a specific existing section in the supplied text. Its stated goal is to set rules for drugs covered by the federal Medicare Drug Price Negotiation Program. The bill was introduced and referred to the Senate Health and Human Services Committee; it is not law. If enacted, it would take effect January 1, 2027.

  • Drug manufacturers could not accept more than the federal “maximum fair price” for covered drugs sold for use in Minnesota, plus applicable dispensing and provider administration fees.
  • Health plans and pharmacy benefit managers (PBMs) would have to reimburse pharmacies at least the greater of the maximum fair price or the national average drug acquisition cost (NADAC), plus an established dispensing fee.
  • Health plans and PBMs would have to give the Prescription Drug Affordability Board specified payment and fee information about these drugs when the Board requests it.
  • A manufacturer withdrawing a covered drug to avoid the price rules would have to notify the health commissioner in writing within the 180 days before withdrawal. A violation would bring a civil penalty of at least $100,000, or the drug’s annual savings as determined by the Board, whichever is greater.

What it means for you#

  • People using these drugs: The bill does not directly set what a patient pays out of pocket, change insurance coverage, or require a manufacturer to keep a drug on sale. It does not say whether any change in payments would be passed on to patients.
  • Drug manufacturers: The price limit would apply to covered drugs intended for use in Minnesota, including sales in person, by mail, or by other means. The bill does not prohibit withdrawal if the manufacturer gives the required notice.
  • Health plans and PBMs: They would have to meet the minimum pharmacy reimbursement rule and provide the Board with the listed information upon request.
  • Pharmacies: For covered drugs, reimbursement could not be below the greater of the maximum fair price or NADAC, plus an established dispensing fee. The bill also says pharmacies may receive a dispensing fee above the maximum fair price.
  • The health commissioner and the Board: The commissioner would assess penalties for violations of the withdrawal rule. The Board would determine annual savings for the penalty calculation and could request financial information.

Money#

No cost estimate is provided in the available material.

  • The bill sets limits and minimums for certain payments, but does not estimate how they would change total spending by health plans, PBMs, manufacturers, pharmacies, or patients.
  • It requires health plans and PBMs to supply information upon request, but gives no staffing or administrative cost estimate.
  • It creates a penalty formula but does not estimate how many penalties, if any, would be assessed.

What is unclear#

  • The supplied materials do not include the existing statutes cited in the bill, so it is not possible to verify how these rules would interact with current law or how terms such as “health plan” are defined there.
  • The bill does not explain how the price limit would account for rebates, fees, adjustments, or reconciliations when determining what a manufacturer accepts.
  • It does not define “established dispensing fee” or explain how that fee is set.
  • The withdrawal rule does not say what counts as withdrawing a drug “for the purpose of avoiding” the price limits. Its wording calls for notice within the 180 days before withdrawal, but does not specify a minimum notice period.
  • The bill does not explain how the Board would calculate “annual savings” for a penalty, or what process manufacturers could use to challenge that calculation.

Case for#

  • A possible argument for the bill is that it would extend a federal negotiated-price benchmark to certain drug sales in Minnesota, rather than leave those sales outside the price limit.
  • The pharmacy reimbursement minimum could help ensure that pharmacies receive at least a specified benchmark or acquisition-cost amount, plus a dispensing fee.
  • Requiring detailed payment information upon request could give the Board more information about the costs and fees tied to these drugs.
  • Notice and penalties could discourage manufacturers from withdrawing a drug without informing the state when the withdrawal is meant to avoid the price rules.

Case against#

  • The bill does not ensure that a drug remains available in Minnesota: a manufacturer could withdraw it after giving notice.
  • The pharmacy reimbursement floor could be higher than the maximum fair price when NADAC is higher. That could mean higher payments by health plans or PBMs, though the bill provides no estimate.
  • The bill does not say whether lower payments would reduce patient costs or improve access.
  • The withdrawal rule and penalty calculation leave important terms and procedures unclear, which could make compliance and enforcement harder.